The 22nd China International In Vitro Diagnostic Expo by CACLP will take place from 22-24 March 2025 at the Hangzhou Grand Convention & Exhibition Center in Hangzhou, China, alongside a range of concurrent activities starting from 21 March to enhance the overall event experience.

Taking place 22-24 March at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025—the 22nd China International In Vitro Diagnostic Expo—will make a significant impact, bringing a sharp focus to global innovation and industry collaboration. With the theme "Innovation for a Better Future", the event is set to bring together industry leaders and emerging players. The preliminary exhibitor list features an impressive range of global participants, ready to showcase cutting-edge advancements and connect with local resources in China’s fast growing in vitro diagnostics (IVD) market.

Dear Exhibitors and Industry Colleagues, Many thanks for your strong support of CACLP Nanchang Expo 2020. With the recent situation caused of the Novel Coronavirus (2019-nCov), Chinese government has initiated the first-level response mecha

On February 7, 2014, China Food and Drug Administration (CFDA) issued the Special Review and Approval Procedure for Innovative Medical Devices (interim), which will be put into force as of March 1, 2014. The Procedure is an approval channel

Company: Kyowa Medex Website: www.kyowamx.co.jp Product: Determiner L HbA1c

Company: hotgen Website: www.hotgen.com.cn Product: UPTquik® Lp-PLA2 Kit

Company: AVE Website: www.c-ave.com Product: AVE-562 Fully Automated Feces Analyzer

Company: Liming Website: www.limingbio.com Product: StrongStep® Trichomonas/ Candida Combo

Company: Liming Website: www.limingbio.com Product: StrongStep® Chlamydia trachomatis/ Neisseria gonorrhoeae Combo

Company: Landwind Website: www.landwind.com.cn Product: LW D6580

Company: Landwind Website: /uploads/allimg/180628/1ZU42P3-0.jpg Product: LW C400

The Name of Devices and Model, Name and Address of Manufacture must be unanimously the same as the contents carried in the documents approved by the government of the Country (Region) of Origin, and must be consistent with the contents concerned c